Search

Displaying results 2311 - 2320 of 4345 in total
  1. Drug

    Asparaginase Erwinia chrysanthemi

    go.drugbank.com/drugs/DB08886
    ApprovedInvestigational

    It works by depleting the stores of an important amino acid called asparagine, which is involved in DNA synthesis and cell survival of malignant cells, leading to cell death. … [L149] In June 2021, the recombinant form of asparaginase _Erwinia chrysanthemi_ was approved by the FDA as a component of a chemotherapy regimen to treat acute lymphoblastic leukemia and lymphoblastic

  2. Drug

    XL019

    go.drugbank.com/drugs/DB05243
    Investigational

    An IND for XL019 was filed by Exelixis in May 2007.

  3. Drug

    Linzagolix

    go.drugbank.com/drugs/DB17083
    ApprovedInvestigational

    [A253667] Linzagolix was approved for use in the European Union in June 2022 for the management of symptoms caused by uterine fibroids.[L43627] … As these fibroids are essentially estrogen-dependent phenomena, hormone therapies which suppress estrogen activity - including GnRH receptor antagonists like linzagolix - are thought to be beneficial by

  4. Drug

    Rabies immune globulin, human

    go.drugbank.com/drugs/DB11603
    Approved

    Recommendations for passive and/or active immunization after exposure to an animal suspected of having rabies have been outlined by the National Advisory Committee on Immunization (NACI), the Advisory

  5. Drug

    Biapenem

    go.drugbank.com/drugs/DB13028
    Investigational

    It is a carbapenem antibiotic with a methyl group on the 1-beta position, which gives it stability against degradation by dehydropeptidase I.[A275008]

  6. Drug

    Neisseria meningitidis group a capsular polysaccharide diphtheria toxoid conjugate antigen

    go.drugbank.com/drugs/DB10798
    ApprovedInvestigational

    Neisseria meningitidis group a capsular polysaccharide diphtheria toxoid conjugate antigen is an active intramuscular immunization for the prophylaxis of invasive meningococcal disease caused by *Neisseria

  7. Drug

    Apixaban

    go.drugbank.com/drugs/DB06605
    ApprovedInvestigational

    Apixaban was approved by the FDA on December 28, 2012[L6043].

  8. Drug

    Halcinonide

    go.drugbank.com/drugs/DB06786
    ApprovedWithdrawn

    Halcinonide is marketed under the brand name Halog® by Ranbaxy Laboratories Inc.

  9. Drug

    AT2220

    go.drugbank.com/drugs/DB05200
    Investigational

    AT2220 is an experimental, oral therapy for the treatment of Pompe disease and belongs to a class of molecules known as pharmacological chaperones. It is a small molecule designed to act as a pharmacological chaperone that specifically b...

  10. Drug

    Abaloparatide

    go.drugbank.com/drugs/DB05084
    ApprovedInvestigational

    [L740] It was first approved by the FDA on April 28, 2017,[A256748] for the treatment of osteoporosis in postmenopausal women and is also used to increase bone density in men with osteoporosis. … L740] In October 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended abaloparatide be granted marketing authorization in Europe [L43552] and the drug was fully authorized by